Richard Vanderveer

Most recent articles by Richard Vanderveer

Vantage Point: Marketing Support for Clinical Trials
Vantage Point: Marketing Support for Clinical Trials
Richard Vanderveer
April 1, 2014
4:00 am

Pharmaceutical companies must provide robust marketing support for their clinical trials

Vantage Point: Ringing in the new market
Vantage Point: Ringing in the new market
Richard Vanderveer
December 1, 2013
5:00 am

In 2014, the “new healthcare marketing” will become more discontinuous from the old

DDR on DTC: Relpax
DDR on DTC: Relpax
Richard Vanderveer
August 1, 2012
4:00 am

Relpax, the migraine drug from Pfizer, has just launched a DTC print campaign that is highly disconcerting. Although the drug is strategically positioned against Imitrex, that info is hard to find in the print ads that are currently appearing in general media magazines such as People. And while the Relpax creative team put in a…

Vantage Point: What 2012 could bring
Vantage Point: What 2012 could bring
Richard Vanderveer
December 1, 2011
5:00 am

Wrapping up what was remarkable about the past year, and pondering how the New Year will be the same and/or different.

  • From Our Partners